The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors.
 
Gulam Abbas Manji
Honoraria - Celgene; Cend Therapeutics; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; Exelixis; Ipsen; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Liam James Stanton
No Relationships to Disclose
 
Liner Ge
No Relationships to Disclose
 
Sarah Sta Ana
No Relationships to Disclose
 
John Chrisinger
No Relationships to Disclose
 
Shiny Titus
No Relationships to Disclose
 
Brian William Labadie
No Relationships to Disclose
 
Michael S. May
No Relationships to Disclose
 
Yang Lyu
No Relationships to Disclose
 
Naomi Sender
No Relationships to Disclose
 
Aik-choon Tan
Employment - Bristol-Myers Squibb/Celgene/Juno (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene/Juno (I)
 
Varun Monga
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Hutchison MediPharma (Inst); Oblato (Inst); Pfizer (Inst); Prelude Therapeutics (Inst)
Travel, Accommodations, Expenses - Cogent Biosciences
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; InhibRx; Jazz Pharmaceuticals; SpringWorks Therapeutics
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Cogent Biosciences (Inst); Cornerstone Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Janssen (Inst); Kronos Bio (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
 
Angela C. Hirbe
Honoraria - Empartners
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca; Intellisphere, LLC; SpringWorks Therapeutics
Research Funding - Tango Therapeutics
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim RCV GmBH & Co KG- Licensing- T-019044 Development of a Preclinical NF1-MPNST Platform Suitable for Precision Oncology Drug Discovery and Evaluation. Royalities paid through the University; Deutsches Krebsforschungszentrum-licensing agreement for PDX cell lines. Paid through the University. (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; SpringWorks Therapeutics
 
Shing M Lee
Consulting or Advisory Role - PTC Therapeutics
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - AADi; Agenus; Astex Pharmaceuticals; Bionaut Labs; Boehringer Ingelheim; Concarlo; Gencirq; Ipsen; January Therapeutics; Kirilys Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Shanghai Pharma
Research Funding - Astex Pharmaceuticals; Oxford BioTherapeutics (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Boehringer Ingelheim